BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/29/2014 11:31:00 AM | Browse: 415 | Download: 472
Publication Name World Journal of Gastroenterology
Manuscript ID 5631
Country/Territory Spain
Received
2013-09-18 10:42
Peer-Review Started
2013-09-18 16:56
To Make the First Decision
2013-12-16 18:15
Return for Revision
2013-12-18 09:50
Revised
2014-01-01 00:29
Second Decision
2014-02-20 09:00
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-02-20 09:37
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-04-11 10:16
Publish the Manuscript Online
2014-04-17 13:27
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Topic Highlights
Article Title Role of cetuximab in first-line treatment of metastatic colorectal cancer
Manuscript Source Invited Manuscript
All Author List Miguel Jhonatan Sotelo, Beatriz García-Paredes, Carlos Aguado, Javier Sastre and Eduardo Díaz-Rubio
Funding Agency and Grant Number
Corresponding author Eduardo Díaz-Rubio, MD, PhD, Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Oncology Department, Hospital Clínico San Carlos. Prof. Martín Lagos, s/n, 28040 Madrid, Spain. ediazrubio.hcsc@salud.madrid.org
Keywords Cetuximab; First-line; Metastatic colorectal cancer; Colorectal liver metastases; Elderly patients
Core Tip This article contains updated data regarding biomarkers of response to epidermal growth factor receptor-targeted therapy and reviews the major studies that have evaluated the efficacy of cetuximab in the first-line treatment of metastatic colorectal cancer (mCRC). We have also compiled the most important data supporting the use of cetuximab in the neoadjuvant treatment of colorectal liver metastases. Finally, we review the current evidence regarding the efficacy and safety of cetuximab in the treatment of elderly patients with mCRC.
Publish Date 2014-04-17 13:27
Citation Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(15): 4208-4219
Url http://www.wjgnet.com/1007-9327/full/v20/i15/4208.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i15.4208
Full Article (PDF) WJG-20-4208.pdf
Full Article (Word) WJG-20-4208.doc
Manuscript File 5631-Review.docx
Answering Reviewers 5631-Answering reviewers.pdf
Copyright License Agreement 5631-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 5631-Language certificate.pdf
Peer-review Report 5631-Peer reviewer(s).pdf
Scientific Editor Work List 5631-Scientific editor work list.doc